About the Authors
- Mark Paul-Clark
-
¶‡ These authors are joint first-authors.
Affiliation Imperial College London, London, United Kingdom
- Wagdi Elsheikh
-
¶‡ These authors are joint first-authors.
Affiliation Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- Nicholas Kirkby
-
Affiliation Imperial College London, London, United Kingdom
- Melissa Chan
-
Affiliation William Harvey Research Institute, London, United Kingdom
- Pallavi Devchand
-
Affiliation Mount Sinai Hospital, Icahn Medical Institute, New York, United States of America
- Terence A. Agbor
-
Affiliation Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- Kyle L. Flannigan
-
Affiliation Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- Charlotte Cheadle
-
Affiliation Imperial College London, London, United Kingdom
- Maxim Freydin
-
Affiliation Imperial College London, London, United Kingdom
- Angela Ianaro
-
Affiliation Department of Experimental Pharmacology, Universita di Napoli Federico II, Napoli, Italy
- Jane A. Mitchell
-
Affiliation Imperial College London, London, United Kingdom
- John L. Wallace
-
* E-mail: altapharm@hotmail.com
Affiliations Department of Physiology & Pharmacology, University of Calgary, Calgary, Alberta, Canada, Faculty of Medicine, Universidade Camilo Castelo Branco, São Paulo, SP, Brazil
Competing Interests
Dr. Wallace is the founder and a director of Antibe Therapeutics, which is developing ATB-346 as an anti-inflammatory drug. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MPC WE NK MC TAA KLF CC JAM JLW. Performed the experiments: MPC WE NK MC TAA KLF CC. Analyzed the data: MPC WE NK PD CC MF AI JAM JLW. Wrote the paper: MPC WE NK JAM JLW.